77·¶ÎÄÍø - רҵÎÄÕ·¶ÀýÎĵµ×ÊÁÏ·ÖÏíÆ½Ì¨

·ÀÖΰ©Ö¢½¡¿µÐû´«Ã½ÌåʵÓÃÊÖ²á(8)

À´Ô´£ºÍøÂçÊÕ¼¯ ʱ¼ä£º2019-02-15 ÏÂÔØÕâÆªÎĵµ ÊÖ»ú°æ
˵Ã÷£ºÎÄÕÂÄÚÈݽö¹©Ô¤ÀÀ£¬²¿·ÖÄÚÈÝ¿ÉÄܲ»È«£¬ÐèÒªÍêÕûÎĵµ»òÕßÐèÒª¸´ÖÆÄÚÈÝ£¬ÇëÏÂÔØwordºóʹÓá£ÏÂÔØwordÓÐÎÊÌâÇëÌí¼Ó΢ÐźÅ:»òQQ£º ´¦Àí£¨¾¡¿ÉÄܸøÄúÌṩÍêÕûÎĵµ£©£¬¸ÐлÄúµÄÖ§³ÖÓëÁ½⡣µã»÷ÕâÀï¸øÎÒ·¢ÏûÏ¢

ÈéÏÙ°©

ÈéÏÙµ¼¹ÜÉÏÆ¤Ï¸°ûÔÚ¸÷ÖÖÄÚÍâÖ°©ÒòËØµÄ×÷ÓÃÏ£¬Ï¸°ûʧȥÕý³£ÌØÐÔ¶øÒì³£ÔöÉú£¬ÒÔÖ³¬¹ý×ÔÎÒÐÞ¸´µÄÏ޶ȶø·¢Éú°©±äµÄ¼²²¡¡£ÁÙ´²ÒÔÈéÏÙÖ׿éΪÖ÷Òª±íÏÖ¡£ÊÇÅ®ÐÔ×î³£¼ûµÄ¶ñÐÔÖ×ÁöÖ®Ò»¡£¾ßÓз¢²¡Âʸߣ¬ÆÄ¾ßÇÖÏ®ÐÔ£¬µ«²¡³Ì½øÕ¹»ºÂý¡£×ÔÈ»Éú´æÆÚ³¤µÈÌØµã¡£ Ƥ·ô°©£º

³£¼ûµÄ¶ñÐÔÖ×ÁöÖ®Ò»£¬ÒÔ»ùµ×ϸ°û°©ºÍÁÛ״ϸ°û°©×îΪ³£¼û£¬Ô¼Õ¼Æ¤·ô°©µÄ90£¥¡£ºÃ·¢ÓÚÀÏÄêÈË£¬°ãÒÔ51¡«60ËêΪ·¢²¡¸ß·å¡£ÄÐÐÔ¶àÓÚÅ®ÐÔ£¬ÄÐÅ®±ÈÀýÔ¼2:1¡£Ô¼80£¥·¢ÉúÓÚÉíÌåµÄ±©Â¶²¿Î»£¬ÈçÍ·¡¢Ãæ¡¢¾±¡¢ÊÖ±³µÈ²¿Î»£¬ÉÙÊý·¢ÉúÓڷDZ©Â¶²¿Î»¡£Æä·¢Éú¿ÉÄÜÓëÈÕ¹âÆØÉ¹¡¢·ÅÉäÏß¡¢Éé¼Á¡¢½¹ÓÍÑÜ»¯ÎïµÈ³¤ÆÚ´Ì¼¤Óйء£ÉÕÉËñ£ºÛÂýÐÔÀ£Ññ¡¢ÉäÏ߯¤Ñ×µÈÆ¤·ôËðº¦Òà¿É¼Ì·¢¡£ Âѳ²°©£º

·¢ÉúÓÚÂѳ²×éÖ¯µÄ¶ñÐÔÖ×Áö¡£Âѳ²°©Æð²¡ÒþÄ䣬ÔçÆÚ²»Ò×·¢ÏÖ£¬Ò××ªÒÆ£¬Ô¤ºó²î¡£Âѳ²¶ñÐÔÖ×ÁöµÄ·¢²¡ÂÊÔÚÅ®ÐÔ³£¼û¶ñÐÔÖ×ÁöÖÐËùÕ¼µÄ°Ù·ÖÂÊΪ2.4£­5.6%£¬ÔÚÅ®ÐÔÉúÖ³µÀ¶ñÐÔÖ×ÁöÖÐÕ¼µÚÈý룬´ÎÓÚ¹¬¾±°©ºÍ¹¬Ìå°©£¬Âѳ²°©ÊÇÔì³ÉËÀÍöÔ­Òò×î¸ßµÄÒ»ÖÖÉúÖ³µÀ¶ñÐÔÖ×Áö¡£ ¹Ç°©£º

¹Ç÷Àϵͳ¼µÄÀ´×ÔÈκÎ×éÖ¯³É·ÝÖ×Áö»òÀ´×ÔÆäËûÆ÷¹ÙµÄ×ªÒÆÐÔ²¡±ä£¬¿É·¢Éúì¶¹Çϸ°û¡¢¹Ç÷ÀµÄÔìѪ³É·Ý, Èí¹ÇÒÔ¼°ÏËάÐÔ»ò»¬Ä¤³É·Ý£¬°üÀ¨¶à·¢ÐÔ¹ÇËèÁö¡¢¹ÇÐÔÈâÁö¡¢Èí¹ÇÈâÁö¡¢ÏËάÈâÁö¡¢ÓÈÓ¦ÊÏÈâÁö, µ«×î³£¼ûµÄ¶ñÐÔ¹ÇÁö²¡ÔîÊǰ©×ªÒÆÖÁ¹ÇÍ·¡£¹ÇÖ×Áö·¢²¡ÄêÁäÄÐÐÔΪ15¡«24Ë꣬ŮÐÔΪ5¡«14Ëê¡£Ö×Áö¿ÉÓоֲ¿ÇÖÏ®ÐÔ£¬¿É¶ñ±äΪ¹ÇÈâÁö¼°·¢Éú·Î²¿×ªÒÆ¡£ ´ó³¦°©£º

×Ô´ó³¦Õ³Ä¤ÉÏÆ¤ÆðÔ´µÄ¶ñÐÔÖ×Áö£¬ÊÇ×î³£¼ûµÄÏû»¯µÀ¶ñÐÔÖ×ÁöÖ®Ò»¡£ÁÙ´²³£¼ûѪ±ã»òճҺŧѪ±ã£¬´ó±ãÐÎ×´»òϰ¹ß·¢Éú¸Ä±ä£¬¸¹Í´£¬¸¹²¿°ü¿éµÈ¡£ÔçÆÚ³£ÎÞÃ÷ÏÔµÄÁÙ´²±íÏÖ£¬²¡Çé·¢Õ¹½ÏÂý£¬Ô¶ÆÚÁÆÐ§ÓÅÓÚÆäËûÏû»¯µÀ¶ñÐÔÖ×Áö£¬µ«·¢²¡Âʸ߲¢ÓÐÁ¬ÄêÉÏÉýÇ÷ÊÆ¡£ ÒýÆð´ó³¦°©µÄÔ­Òò

ÒûʳÒòËØ£¨Èç¸ßÖ¬·¾Òûʳ¡¢µÍÏËάÒûʳ¡¢¶¯Îïµ°°×¡¢Ê³ÎïÖÐÑÇÏõ°·¼°ÆäÑÜÉúÎﺬÁ¿¸ß£»ÉãÈ˾ƾ«¡¢Î¬ÉúËØA¼°Î¢Á¿ÔªËØÈ±·¦µÈ£©£»´ó³¦µÄijЩÁ¼ÐÔ²¡±äÈçÂýÐÔÀ£ÑñÐԽ᳦Ñ×£¬´ó³¦ÏÙÁöÓë¼Ò×åÐԽ᳦ÏÙÁö²¡£¬ÑªÎü³æ²¡µÈ£»ÒÔ¼°ÒÅ´«ÒòËØÈç¼Ò×åÐÔÏÙÁöÐÔÏ¢Èⲡ£¬ÒÅ´«ÐÔ·ÇÏ¢ÈⲡÐÔ½áÖ±³¦°©µÈ¡£ ¹¬¾±°©

×Ó¹¬¾±°©£¬Ö¸·¢ÉúÔÚ¹¬¾±ÒõµÀ²¿»òÒÆÐдøµÄÁÛ×´ÉÏÆ¤Ï¸°û¼°¹¬¾±¹ÜÄÚĤµÄÖù×´ÉÏÆ¤Ï¸°û½»½ç´¦µÄ¶ñÐÔÖ×Áö£¬ÔÚÔçÆÚÁÙ´²±íÏÖ¿ÉÎÞÈκÎÖ¢×´¡£ÓÉÓÚÆä·¢ÉúµÄ²¿Î»ºÍÒõµÀϸ°ûѧ¼ì²éµÄÓ¦Óã¬

¿É±»ÔçÆÚ·¢ÏÖ²¢»ý¼«Ô¤·À£¬ÖÎÁÆÐ§¹û½ÏºÃ£¬½üÄêÀ´·¢²¡ÂʺÍËÀÍöÂÊÓдó·ù¶ÈϽµ¡£ ³£¼ûÓ¢ÎÄËõд B

BRM Biological Response Modifiers ÉúÎï·´Ó¦µ÷½ÚÖÆ¼Á C

CABG ÌåÍâÑ­»·¹Ú×´¶¯ÂöÅÔÂ·ÒÆÖ²Êõ CEA °©Åß¿¹Ô­ chemotherapy »¯Ñ§ÖÎÁÆ

CLL Chronic Lymphocytic Leukaemia ÂýÐÔÁܰÍϸ°ûÐÔ°×Ѫ²¡ CML ÂýÐÔ¹ÇËè°×Ѫ²¡ colorectal cancer ½á³¦°©

CT computed tomography ¼ÆËã»úXÏßÌå²ãÉãÓ° cTNM ÖÎÁÆÇ°µÄ·ÖÆÚ Curative treatment ¸ùÖÎÁÆ·¨ CYFRA 21-1 ϸ°û½Çµ°°×21-1Ƭ¶Î D

DSA Êý×ÖѪ¹ÜÔìÓ° E

ELISA øÁªÃâÒßÎü¸½·¨

ERCP ÄÚ¾µÄæÐÐÒȵ¨¹ÜÔìÓ°Êõ¼¼Êõ

EUC endometrial undifferentiated carcinoma ×Ó¹¬ÄÚĤδ·Ö»¯°© G

G£¬ Grad Ö×Áöϸ°û·Ö»¯³Ì¶È¡£

--G1£¬¼´¸ß·Ö»¯£¬Ï¸°û·Ö»¯³Ì¶È½ÏºÃ¡£Ò»°ãÀ´Ëµ£¬G1µÄÖ×Áöϸ°û·ÖÁÑËٶȽÏÂý¡£ --G2£¬¼´Öзֻ¯£¬Ï¸°û·Ö»¯³Ì¶È¾ÓÖС£

--G3£¬¼´µÍ·Ö»¯£¬Ï¸°û·Ö»¯³Ì¶È½Ï²î¡£Ö×Áöϸ°û·ÖÁÑËٶȽϿ졣

H

HCL Á£Ï¸°û°×Ѫ²¡

HIFU high-intensity focused ultrasound ¸ßÇ¿¶È¾Û½¹³¬Éù¼¼Êõ HNSCC Í·¾±²¿ÁÛ°© HPV ÈËÀàÈéÍ·Áö²¡¶¾ I

IFN-¦Á ¦ÁÐ͸ÉÈÅËØ IL-2 2ÐͰ×ϸ°û¼ä½éËØ M

Mx Ô¶´¦×ªÒÆ´æÔÚÓë·ñ²»ÄÜÈ·¶¨£» M0 Ô¶´¦×ªÒƲ»´æÔÚ£» M1 Ô¶´¦×ªÒÆ´æÔÚ

MST Median Survival Time ÖÐλÉú´æÆÚ MR ºÃת

MRI magnatic resonance imaging ´Å¹²Õñ³ÉÏñÊõ MRCP ºË´Å¹²ÕñÒȵ¨¹ÜÔìÓ° N

Neoadjuvant therapy и¨ÖúÁÆ·¨ HL »ôÆæ½ðÁܰÍÁö NHL ·Ç»ôÆæ½ðÁܰÍÁö

NSCLC non-small cell lung cancer ·ÇСϸ°û·Î°© Nx ¡ªÇøÓòÁÜ°Í½á£¨×ªÒÆ£©²»Ã÷£» N0 ¡ªÎÞÇøÓòÁܰͽá×ªÒÆ£» P

Palliative treatment ¹ÃÏ¢ÁÆ·¨

PCT Photochemical Therapy¹â»¯Ñ§ÁÆ·¨ PCS ƤÏÂÒ©ºÐÂñÖ²Êõ

PDD Photodynamic Diagnosis Ó«¹âÕï¶Ï PDT Photodynamic Therapy ¹â¶¯Á¦ÁÆ·¨ PET Õýµç×Ó·¢ÉäÌå²ãɨÃè PR ²¿·Ö»º½â

PRFA Percutaneous radio-frequcncy ablatiOn ÖÎÁƾ­Æ¤É䯵»ÙËð P roGRP θÃÚËØÊÍ·ÅëÄǰÌå

PRT Photoradiation Therap¹â·øÉäÁÆ·¨ PTA ¾­Æ¤Ç»ÄÚѪ¹Ü³ÉÐÎÊõ PTC ¾­Æ¤¾­¸Îµ¨µÀÔìÓ° PTCA ¾­Æ¤¹Ú×´¶¯ÂöÄÚĤ³ÉÐÍÊõ PTCD ¾­Æ¤´©¸Îµ¨¹ÜÒýÁ÷Êõ

pTNM p£ºPathology TMN²¡Àí·ÖÆÚ R

Remission »º½â RIA ·ÅÉäÃâÒß·ÖÎö·¨ RFA É䯵ÖÎÁÆ S

SCC squamous cell carcinomaÁÛ״ϸ°û°© SCC ÁÛ״ϸ°û°©¿¹Ô­

SCLC small cell lung cancer Сϸ°û·Î°© SCC-Ag ÁÛ״ϸ°û°©Ïà¹Ø¿¹Ô­ SD ¼²²¡Îȶ¨ T

TNM·ÖÆÚϵͳ The TNM Staging System --T£ºTumor£¨Topography£© Ô­·¢Ö×ÁöµÄ·¶Î§£»

--N£ºLymph Node ÇøÓòÁܰͽá×ªÒÆµÄ´æÔÚÓë·ñ¼°·¶Î§£» --M£ºMetastasis Ô¶´¦×ªÒƵĴæÔÚÓë·ñ¡£ Tx ¡ªÔ­·¢Ö×Áö²»ÄÜÈ·¶¨£» T0 ¡ªÎÞÔ­·¢Ö×ÁöµÄÖ¤¾Ý£» Tis¡ªÔ­Î»°©£¨is´ú±í in situԭ룩

T1¡¢T2¡¢T3¡¢T4 ¡ªÔ­·¢Ö×ÁöµÄÌå»ý¼°/»ò·¶Î§µÝÔö£¬Êý×ÖÔ½´ó£¬Ö×ÁöÀÛ¼°µÄ·¶Î§»ò³Ì¶ÈÔ½´ó¡£

TACE transcatheter arterial chemoembolization ¸Î¶¯Âö²å¹Ü»¯ÁÆ¡¢Ë¨Èû·½·¨£¨½éÈëÁÆ·¨£© TAE ¾­µ¼¹Ü¸Î¶¯Âö˨ÈûÊõ TPA ×éÖ¯¶àëÄ¿¹Ô­ TTP Ö×Áö½øÕ¹Ê±¼ä

TM tumour marker Ö×Áö±êÖ¾ V

VEGF Vascular Endothelial Growth Factor Ѫ¹ÜÄÚÆ¤Éú³¤Òò×Ó

? Ïà¹ØÍøÖ·

ËÑË÷ÒýÇæ

MadWebËÑË÷ÒýÇæ

http://www.medweb.emory.edu/medweb/

Medic8-Ó¢ÎÄËÑË÷ÒýÇæ http://www.medic8.com/

ÔÚÏß°©Ö¢×ÊÔ´ËÑË÷

http://www.cancersource.com/

MedmarkÓ¢Óï×ßË÷ÒýÇæ http://www.medmark.org/

HealthwebÓ¢ÓïËÑË÷ÒýÇæ http://healthweb.org/

TeleSCAN:ºÉÀ¼Å·ÖÞ°©Ö¢×ÊÔ´¼ìË÷

http://telescan.nki.nl/

Ö×ÁöѧËÑË÷ÒýÇæ

°Ù¶ÈËÑË÷¡°77cn¡±»ò¡°Ãâ·Ñ·¶ÎÄÍø¡±¼´¿ÉÕÒµ½±¾Õ¾Ãâ·ÑÔĶÁÈ«²¿·¶ÎÄ¡£Êղر¾Õ¾·½±ãÏ´ÎÔĶÁ£¬Ãâ·Ñ·¶ÎÄÍø£¬Ìṩ¾­µäС˵×ÛºÏÎÄ¿â·ÀÖΰ©Ö¢½¡¿µÐû´«Ã½ÌåʵÓÃÊÖ²á(8)ÔÚÏßÈ«ÎÄÔĶÁ¡£

·ÀÖΰ©Ö¢½¡¿µÐû´«Ã½ÌåʵÓÃÊÖ²á(8).doc ½«±¾ÎĵÄWordÎĵµÏÂÔØµ½µçÄÔ£¬·½±ã¸´ÖÆ¡¢±à¼­¡¢ÊղغʹòÓ¡ ÏÂÔØÊ§°Ü»òÕßÎĵµ²»ÍêÕû£¬ÇëÁªÏµ¿Í·þÈËÔ±½â¾ö£¡
±¾ÎÄÁ´½Ó£ºhttps://www.77cn.com.cn/wenku/zonghe/465951.html£¨×ªÔØÇë×¢Ã÷ÎÄÕÂÀ´Ô´£©

Ïà¹ØÍÆ¼ö£º

Copyright © 2008-2022 Ãâ·Ñ·¶ÎÄÍø °æÈ¨ËùÓÐ
ÉùÃ÷ :±¾ÍøÕ¾×ðÖØ²¢±£»¤ÖªÊ¶²úȨ£¬¸ù¾Ý¡¶ÐÅÏ¢ÍøÂç´«²¥È¨±£»¤ÌõÀý¡·£¬Èç¹ûÎÒÃÇ×ªÔØµÄ×÷Æ·ÇÖ·¸ÁËÄúµÄȨÀû,ÇëÔÚÒ»¸öÔÂÄÚ֪ͨÎÒÃÇ£¬ÎÒÃǻἰʱɾ³ý¡£
¿Í·þQQ£º ÓÊÏ䣺tiandhx2@hotmail.com
ËÕICP±¸16052595ºÅ-18
¡Á ×¢²á»áÔ±Ãâ·ÑÏÂÔØ£¨ÏÂÔØºó¿ÉÒÔ×ÔÓɸ´ÖƺÍÅŰ棩
×¢²á»áÔ±ÏÂÔØ
ȫվÄÚÈÝÃâ·Ñ×ÔÓɸ´ÖÆ
×¢²á»áÔ±ÏÂÔØ
ȫվÄÚÈÝÃâ·Ñ×ÔÓɸ´ÖÆ
×¢£ºÏÂÔØÎĵµÓпÉÄÜ¡°Ö»ÓÐĿ¼»òÕßÄÚÈݲ»È«¡±µÈÇé¿ö£¬ÇëÏÂÔØÖ®Ç°×¢Òâ±æ±ð£¬Èç¹ûÄúÒѸ¶·ÑÇÒÎÞ·¨ÏÂÔØ»òÄÚÈÝÓÐÎÊÌ⣬ÇëÁªÏµÎÒÃÇЭÖúÄã´¦Àí¡£
΢ÐÅ£º QQ£º